Commitment and Contingencies - Additional Information (Details) € in Thousands |
Sep. 30, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Jun. 30, 2018
USD ($)
|
Jun. 30, 2018
EUR (€)
|
Jun. 30, 2016
USD ($)
|
Jun. 30, 2016
EUR (€)
|
Nov. 18, 2015
USD ($)
|
---|---|---|---|---|---|---|---|
Other Commitments [Line Items] | |||||||
Purchase obligation | $ 164,000 | $ 1,604,000 | $ 2,727,000 | € 2,500 | |||
Pfizer License Agreement | Minimum | |||||||
Other Commitments [Line Items] | |||||||
Potential future regulatory milestone and sales milestone payments upon achievement of net sales | $ 250,000,000 | ||||||
Pfizer License Agreement | Maximum | |||||||
Other Commitments [Line Items] | |||||||
Potential future regulatory milestone and sales milestone payments upon achievement of net sales | $ 1,000,000,000 | ||||||
Supplemental Agreement | |||||||
Other Commitments [Line Items] | |||||||
Purchase obligation | $ 2,236,000 | € 2,050 |
X | ||||||||||
- Definition Potential future regulatory and sales milestone payments upon achievement of net sales. No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|